Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Acusphere, Inc.

Market Cap 3.46M 2.99M 2.76M 2.58M 4.84M 329M 4.91M 32.56M 12.7M 160M 13M 12.73M 555M P/E Ratio 2006
-1.06x
P/E Ratio 2007 -0.49x
Enterprise Value -11.29M -9.75M -8.99M -8.41M -15.77M -1.07B -16.01M -106M -41.38M -522M -42.38M -41.48M -1.81B EV / Sales 2006
9,811,030x
EV / Sales 2007 5,744,305x
Free-Float
100%
Yield 2006 *
-
Yield 2007 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%+1.43%+7.13%+83.44% 45.63B
-0.20%-3.59%+38.01%+87.26% 33.53B
+0.44%-0.85%-7.55%+44.74% 11.81B
-0.11%+1.44%+12.86%+116.61% 11.69B
+0.59%+0.78%+36.70%+126.43% 9.12B
+2.40%+0.08%+17.77%+43.22% 7.16B
-1.12%-0.56%+40.12%-18.60% 6.49B
+1.37%+0.35%+32.58%+240.43% 6.45B
+0.51%-3.04%-42.24%-5.52% 5.16B
Average +0.51%-0.07%+15.04%+79.78% 15.23B
Weighted average by Cap. +0.42%-0.30%+17.34%+83.84%

Financials

2006 2007
Net sales 1.78 1.54 1.42 1.33 2.49 169.29 2.53 16.74 6.53 82.4 6.68 6.54 285.3 2.67 2.3 2.12 1.99 3.72 253.5 3.78 25.06 9.77 123.39 10.01 9.8 427.23
Net income -61.09M -52.76M -48.62M -45.51M -85.29M -5.81B -86.61M -574M -224M -2.83B -229M -224M -9.79B -53.73M -46.41M -42.76M -40.03M -75.02M -5.11B -76.18M -505M -197M -2.49B -202M -197M -8.61B
Net Debt -52.87M -45.67M -42.08M -39.39M -73.82M -5.03B -74.96M -497M -194M -2.45B -198M -194M -8.47B -14.76M -12.75M -11.75M -10.99M -20.6M -1.4B -20.92M -139M -54.07M -683M -55.39M -54.21M -2.36B
Logo Acusphere, Inc.
Acusphere, Inc. is a specialty pharmaceutical company. The Company is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The Company's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The Company has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!